These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8905027)

  • 21. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
    Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
    Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer.
    Kwa HB; Michalides RJ; Dijkman JH; Mooi WJ
    Lung Cancer; 1996 Jun; 14(2-3):207-17. PubMed ID: 8794404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression.
    Barbareschi M; Pelosio P; Caffo O; Buttitta F; Pellegrini S; Barbazza R; Dalla Palma P; Bevilacqua G; Marchetti A
    Int J Cancer; 1997 Apr; 74(2):171-4. PubMed ID: 9133450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
    Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas.
    Jares P; Fernández PL; Campo E; Nadal A; Bosch F; Aiza G; Nayach I; Traserra J; Cardesa A
    Cancer Res; 1994 Sep; 54(17):4813-7. PubMed ID: 8062283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
    Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
    Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer.
    Betticher DC; Heighway J; Hasleton PS; Altermatt HJ; Ryder WD; Cerny T; Thatcher N
    Br J Cancer; 1996 Feb; 73(3):294-300. PubMed ID: 8562333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of cyclin Ds in relation to p53 status in human breast carcinomas.
    Bukholm IK; Berner JM; Nesland JM; Børresen-Dale AL
    Virchows Arch; 1998 Sep; 433(3):223-8. PubMed ID: 9769125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin D1 overexpression in primary hypopharyngeal carcinomas.
    Masuda M; Hirakawa N; Nakashima T; Kuratomi Y; Komiyama S
    Cancer; 1996 Aug; 78(3):390-5. PubMed ID: 8697381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 67-kDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer.
    Gasparini G; Barbareschi M; Boracchi P; Bevilacqua P; Verderio P; Dalla Palma P; Ménard S
    Int J Cancer; 1995 Mar; 60(5):604-10. PubMed ID: 7860133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.
    Gillett C; Fantl V; Smith R; Fisher C; Bartek J; Dickson C; Barnes D; Peters G
    Cancer Res; 1994 Apr; 54(7):1812-7. PubMed ID: 8137296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype.
    Mylona E; Tzelepis K; Theohari I; Giannopoulou I; Papadimitriou C; Nakopoulou L
    Histopathology; 2013 Feb; 62(3):472-80. PubMed ID: 23163571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers.
    Shin KY; Kong G; Kim WS; Lee TY; Woo YN; Lee JD
    Br J Cancer; 1997; 75(12):1788-92. PubMed ID: 9192983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
    Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.
    Cheng CW; Liu YF; Yu JC; Wang HW; Ding SL; Hsiung CN; Hsu HM; Shieh JC; Wu PE; Shen CY
    Ann Surg Oncol; 2012 Dec; 19(13):4129-39. PubMed ID: 22864797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.